Our team

Rebecca V. Frey, Pharm.D.

Venture Partner

Rebecca Frey brings twenty-five years of drug development experience to her role as a Venture Partner at RTW. In this capacity she is leading the buildout efforts for RTW's newly formed companies.

Throughout her career, Rebecca has focused on solving important problems for patients with serious diseases. She has worked across small and large biopharma companies, including as CEO and COO in emerging biotech startups. In recent years, Rebecca has been involved in the builds of several biotech companies including Siduma Therapeutics, EvolveImmune Therapeutics and Cardurion Pharmaceuticals. Rebecca previously held multiple leadership roles at Alexion Pharmaceuticals where she spearheaded the development of Soliris in multiple successful expansion indications. Prior to Alexion she worked in clinical operations and medical affairs at Novartis Pharmaceuticals.

Across her career, Rebecca has contributed to the development of five approved drug products and three approved expansion indications. Rebecca serves as an independent board member for Halda Therapeutics and Octant, and as the Executive Chair of Artelis Biopharma. She is a certified board director by the National Association of Corporate Directors. Rebecca holds a Doctor of Pharmacy degree from Northeastern University where she also completed a postgraduate research fellowship.

Building impactful biotech companies requires significant vision and teamwork to transform nascent ideas into meaningful shareholder value. It is a privilege to work at the intersection of science and entrepreneurship to create leading biotech companies. Each new RTW venture has the potential to shape the future of medicine for patients around the world. I am proud to be a part of the RTW team, where innovation and excellence underpin everything we do.

Share profile

Back to our team

This website is not intended to offer or to promote the offer or sale of the shares (the “Shares”) of RTW Biotech Opportunities Ltd (the “Company”) in the United States or to any “U.S. persons” as defined in Regulation S (“US persons”) under the US Securities Act of 1933, as amended (the “Securities Act”). The materials contained herein are not for release, publication or distribution, directly or indirectly, in whole or in part, to any persons to whom or into or within any jurisdiction where to do so would constitute a violation of applicable law or regulation.

The information contained herein and on the pages that follow does not constitute or form a part of any offer to sell or issue, or the solicitation of any offer to purchase, subscribe for or otherwise acquire, any securities in the United States or in any jurisdiction in which, or to any person to whom, such an offer or solicitation would be unlawful.

The Company has not been and will not be registered under the US Investment Company Act of 1940, as amended (the “Investment Company Act”), and as such holders of the Shares are not and will not be entitled to the benefits of the Investment Company Act. The Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, delivered, assigned or otherwise transferred, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not result in the Company being required to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. The offer and sale of the Shares have not been and will not be registered under the applicable securities laws of Australia, Canada, Japan or South Africa. Potential users of the information contained herein and on the pages that follow are requested to inform themselves about and to observe all applicable restrictions.

The information contained herein and on the pages that follow may contain forward-looking statements. Any statement other than a statement of historical fact is a forward-looking statement. Actual results may differ materially from those expressed or implied by any forward-looking statement. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. You should not place undue reliance on any forward-looking statement, which speaks only as of the date of its issuance. The Company may change these terms and conditions from time to time and any such changes will be posted on this website. Your access to this website is governed by the version of these terms and conditions then in force.

By clicking “Agree” below, you represent, warrant, undertake and agree that (1) you have read, understood and agree to be bound by the terms and conditions and other information set out herein, (2) you are permitted under applicable laws and regulations to receive the information contained herein and on the pages that follow, (3) you are either (a) located outside the United States and are not a US Person or (b) an existing shareholder of the Company who is a “qualified purchaser” as defined under the Investment Company Act and (4) you will not further transmit or send any information contained in this website to any other persons in the United States, to US Persons, or to any publications with a general circulation in the United States. If you cannot so represent, warrant, undertake and agree, you must click the button labelled “Decline” or otherwise exit this website.